143 related articles for article (PubMed ID: 26611601)
1. Gene Therapy-Based Modeling of Neurodegenerative Disorders: Huntington's Disease.
Young D
Methods Mol Biol; 2016; 1382():383-95. PubMed ID: 26611601
[TBL] [Abstract][Full Text] [Related]
2. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
[TBL] [Abstract][Full Text] [Related]
3. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
[TBL] [Abstract][Full Text] [Related]
4. [Mechanisms of neuronal death in Huntington's disease. First part: general considerations and histopathological features].
Bantubungi K; Blum D
Rev Med Brux; 2007; 28(5):413-21. PubMed ID: 18069515
[TBL] [Abstract][Full Text] [Related]
5. Huntington's disease: from molecular pathogenesis to clinical treatment.
Ross CA; Tabrizi SJ
Lancet Neurol; 2011 Jan; 10(1):83-98. PubMed ID: 21163446
[TBL] [Abstract][Full Text] [Related]
6. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
[TBL] [Abstract][Full Text] [Related]
7. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modifications as novel therapeutic targets for Huntington's disease.
Wang F; Fischhaber PL; Guo C; Tang TS
Epigenomics; 2014 Jun; 6(3):287-97. PubMed ID: 25111483
[TBL] [Abstract][Full Text] [Related]
9. Huntington's disease: genetics lends a hand.
Palfi S; Jarraya B
Nature; 2008 Jun; 453(7197):863-4. PubMed ID: 18488017
[No Abstract] [Full Text] [Related]
10. Mutant huntingtin can paradoxically protect neurons from death.
Zuchner T; Brundin P
Cell Death Differ; 2008 Mar; 15(3):435-42. PubMed ID: 17975550
[TBL] [Abstract][Full Text] [Related]
11. Huntington's disease: From molecular basis to therapeutic advances.
Krobitsch S; Kazantsev AG
Int J Biochem Cell Biol; 2011 Jan; 43(1):20-4. PubMed ID: 21056115
[TBL] [Abstract][Full Text] [Related]
12. [Gene silencing approaches for the treatment of Huntington's disease].
Merienne N; Déglon N
Med Sci (Paris); 2015 Feb; 31(2):159-67. PubMed ID: 25744262
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
[TBL] [Abstract][Full Text] [Related]
14. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
[TBL] [Abstract][Full Text] [Related]
15. Huntington's disease: an update of therapeutic strategies.
Kumar A; Kumar Singh S; Kumar V; Kumar D; Agarwal S; Rana MK
Gene; 2015 Feb; 556(2):91-7. PubMed ID: 25447911
[TBL] [Abstract][Full Text] [Related]
16. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
Wang LH; Qin ZH
Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
[TBL] [Abstract][Full Text] [Related]
17. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease.
Milnerwood AJ; Cummings DM; Dallérac GM; Brown JY; Vatsavayai SC; Hirst MC; Rezaie P; Murphy KP
Hum Mol Genet; 2006 May; 15(10):1690-703. PubMed ID: 16600988
[TBL] [Abstract][Full Text] [Related]
18. Dysfunctional Dopaminergic Neurones in Mouse Models of Huntington's Disease: A Role for SK3 Channels.
Dallérac GM; Levasseur G; Vatsavayai SC; Milnerwood AJ; Cummings DM; Kraev I; Huetz C; Evans KA; Walters SW; Rezaie P; Cho Y; Hirst MC; Murphy KP
Neurodegener Dis; 2015; 15(2):93-108. PubMed ID: 25871323
[TBL] [Abstract][Full Text] [Related]
19. Lentiviral-mediated gene transfer of siRNAs for the treatment of Huntington's disease.
Cambon K; Déglon N
Methods Mol Biol; 2013; 1010():95-109. PubMed ID: 23754221
[TBL] [Abstract][Full Text] [Related]
20. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
